Chronic Abacterial Prostatitis - Clinical Trial (09-02-69)
A Phase 2, 16 Week, Multicenter, Randomized, Double-Blind Placebo Controlled, Parallel Group Proof-of-Concept Study Evaluating the Efficacy and Safety of Tanezumab for the Treatment of Pain Associated with Chronic Abacterial Prostatitis
Protocol ID
Protocol Description
This study is being done to find out the good and bad effects and the safety and effectiveness of an experimental drug called tanezumab for prostatitis (chronic abacterial, or non-infectious, prostatitis). Tanezumab is an antibody that binds to nerve growth factor, which plays a part in the biological processes that cause pain. This study will also look at how tanezumab is processed and broken down by the body when it is given to subjects with chronic prostatitis.
Eligibility Criteria
Patients with prostatitis
Primary Investigator(s)
- Robert Moldin, MD